Rachel Silvestrini serves as the Vice President of Business Insights and Analytics (BI&A) at Eli Lilly and Company, where she spearheads a dynamic team dedicated to harnessing the power of data to drive strategic decision-making within the commercial sector. With a robust background in statistics...
Rachel Silvestrini serves as the Vice President of Business Insights and Analytics (BI&A) at Eli Lilly and Company, where she spearheads a dynamic team dedicated to harnessing the power of data to drive strategic decision-making within the commercial sector. With a robust background in statistics and mathematical modeling, Rachel is adept at transforming complex datasets into actionable insights that inform business strategies and enhance operational efficiency. Her leadership is characterized by a commitment to integrating advanced analytics and artificial intelligence into everyday practices, ensuring that the organization remains at the forefront of innovation in the pharmaceutical industry.
Under Rachel's guidance, the BI&A team has embarked on several key projects that leverage predictive analytics and decision analysis to optimize marketing strategies and improve patient outcomes. By utilizing tools such as JMP and Matlab, her team conducts rigorous data analysis and research, enabling Eli Lilly to make informed decisions that align with market demands and patient needs. Rachel's unique journey from academia to analytics leadership reflects her dedication to continuous learning and adaptation in an ever-evolving industry. She fosters a culture of education within her team, empowering members to embrace analytical insights and AI technologies that enhance their capabilities.
Rachel’s expertise not only drives business performance but also positions Eli Lilly as a leader in leveraging data for impactful healthcare solutions. Her vision for the future of BI&A emphasizes collaboration, innovation, and a relentless pursuit of excellence, ensuring that the organization is well-equipped to navigate the complexities of the pharmaceutical landscape.
